Analytical Data
-
Gene name
PTHR1
- Application
-
Alternative Names
PTHR1；PTHR；PTHR1；Parathyroid hormone/parathyroid hormone-related peptide receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01270
-
Expression Region
32-65aa
-
AA Sequence
SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNF
-
Molecular Weight
4.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Parathyroid hormone receptor 1 (PTHR1) is a G-protein coupled receptor that plays a crucial role in mediating the effects of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) on cellular functions. These hormones are essential for bone metabolism, calcium homeostasis, and the regulation of various physiological processes. Dysregulation of PTHR1 has been implicated in several bone disorders, including osteoporosis and metaphyseal dysplasia, which highlights the importance of understanding its structure and function. Recent advancements in recombinant protein technology have enabled the production of PTHR1 in a laboratory setting, providing a valuable tool for studying its signaling pathways and interactions with ligands. Researchers are particularly interested in the receptor's conformational changes upon hormone binding, as these changes are fundamental to its activation and downstream signaling events. Furthermore, elucidating the mechanisms of PTHR1 may pave the way for the development of novel therapeutics that target bone-related diseases. By using recombinant PTHR1, scientists can perform detailed biochemical assays, high-throughput screening, and structural analysis, thus enhancing our knowledge of its role in health and disease. Overall, the study of PTHR1 recombinant proteins is a promising avenue that could contribute to the discovery of innovative treatments for metabolic bone disorders and improve our understanding of calcium regulation in the human body.
